Parkman Healthcare Partners’s Maravai LifeSciences MRVI Stock Holding History

Parkman Healthcare Partners’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-660,000	Closed	-$1.46M	–	95
2025 Q1	$1.46M	Buy	660,000 +310,000	+89%	+$1.22M	0.17%	80
2024 Q4	$1.91M	Buy	+350,000	New	+$2.25M	0.25%	75
2022 Q2	–	Sell	-77,389	Closed	-$2.73M	–	84
2022 Q1	$2.73M	Sell	77,389 -21,299	-22%	-$714K	0.8%	42
2021 Q4	$4.13M	Buy	98,688 +8,688	+10%	+$352K	0.91%	33
2021 Q3	$4.42M	Hold	90,000	–	–	1.12%	29
2021 Q2	$3.76M	Sell	90,000 -22,500	-20%	-$872K	0.82%	40
2021 Q1	$4.01M	Buy	112,500 +2,224	+2%	+$73.7K	0.93%	36
2020 Q4	$3.09M	Buy	+110,276	New	+$3.07M	0.79%	50

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return

Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Parkman Healthcare Partners's MRVI Position: Q2 2025 in Review

Parkman Healthcare Partners sold out of Maravai LifeSciences (MRVI) in Q2 2025, closing a stake of 660,000 shares — an estimated $1.46M sold.

Parkman Healthcare Partners first reported a position in MRVI in Q4 2020 and held it in 8 quarters. The position peaked at $4.42M in Q3 2021. 150 funds tracked by Wall St. Rank hold MRVI as of Q2 2025.

Parkman Healthcare Partners reported no remaining Maravai LifeSciences position as of Q2 2025 after selling out during the quarter.
Parkman Healthcare Partners sold 660,000 Maravai LifeSciences shares in Q2 2025, an estimated $1.46M.
Parkman Healthcare Partners first reported a position in Maravai LifeSciences in Q4 2020 and held it in 8 quarters.
Parkman Healthcare Partners's Maravai LifeSciences position peaked at $4.42M in Q3 2021.
150 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2025.

Based on Parkman Healthcare Partners's 13F filing for Q2 2025, filed 14 Aug 2025.